Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

RMH Score (Phase I Trials)

The Royal Marsden Hospital (RMH) Score is a prognostic score used to stratify patients referred for Phase I clinical trials.

Evidence-based context for fast calculator use

Purpose:
Royal Marsden Hospital score stratifies advanced cancer patients using albumin, LDH, and metastatic sites to assess Phase I trial eligibility.
Population:
patients whose general oncology assessment matches the intended use of the selected score
Factors:
Albumin < 35 g/L?, LDH > Upper Limit of Normal?, Number of Metastatic Sites > 2?
Reference:
Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009;27(16):2692-2696.
HomeRMH Score (Phase I Trials)
Pin your most used calculators here by clicking the star in the dropdown.

RMH Score (Phase I Trials)

Clinical Context & Background

The Royal Marsden Hospital (RMH) Score is a prognostic score used to stratify patients referred for Phase I clinical trials. It uses three objective markers (Albumin, LDH, Metastases) to predict survival, aiding in patient selection for early-phase studies.
Primary Source EvidenceArkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009;27(16):2692-2696.
Formula Logic
Score 0-3 based on: Albumin < 35 g/L, LDH > ULN, and > 2 Metastatic Sites.

Reference Data

ScoreMedian Overall Survival
0 - 132.6 weeks (Good Prognosis)
2 - 316.7 weeks (Poor Prognosis)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use RMH Score (Phase I Trials) when royal Marsden Hospital score stratifies advanced cancer patients using albumin, LDH, and metastatic sites to assess Phase I trial eligibility.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 1 through 2 - 3.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with diagnosis, disease burden, organ function, frailty, treatment intent, medicines, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • General oncology tools measure one domain and should not become a universal treatment-eligibility rule.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients whose general oncology assessment matches the intended use of the selected score

How to apply this result

For a representative case, verify Albumin < 35 g/L?, LDH > Upper Limit of Normal?, Number of Metastatic Sites > 2?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

ECOG Performance StatusBody Surface Area (BSA)Karnofsky Performance Status (KPS)

Frequently Asked Questions

When should RMH Score (Phase I Trials) be used?

Use it for patients whose general oncology assessment matches the intended use of the selected score when all required inputs and the intended clinical setting are confirmed.

Can RMH Score (Phase I Trials) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.